• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps Over 100 Points; Eli Lilly Posts Upbeat Earnings

    2/6/24 9:52:04 AM ET
    $AGFY
    $BRTX
    $LLY
    $NVIV
    Farming/Seeds/Milling
    Consumer Staples
    Managed Health Care
    Health Care
    Get the next $AGFY alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday.

    Following the market opening Tuesday, the Dow traded up 0.34% to 38,509.84 while the NASDAQ rose 0.21% to 15,629.82. The S&P 500 also rose, gaining, 0.17% to 4,951.38.

    Check This Out: Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday

     

    Leading and Lagging Sectors

     

    Materials shares rose by 0.9% on Tuesday.

    In trading on Tuesday, utilities shares fell by 0.4%.

     

    Top Headline

     

    Eli Lilly And Co (NYSE:LLY) posted better-than-expected earnings for its fourth quarter.

    Eli Lilly reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates. Eli Lilly posted an adjusted EPS of $2.49, beating the consensus of $2.19, up 19% Y/Y.

     

    Equities Trading UP

     

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) shares shot up 168% to $0.5941 after dipping around 26% on Monday.

    Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) got a boost, surging 94% to $17.00 after the company announced the USPTO granted notice of allowance for the U.S. patent application "Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction."

    Agrify Corporation (NASDAQ:AGFY) shares were also up, gaining 42% to $0.91. Agrify achieved milestone with PX-30 hydrocarbon extraction system installation in Michigan Facility.

     

    Equities Trading DOWN

     

    Sunworks, Inc. (NASDAQ:SUNW) shares dropped 66% to $0.0710. Sunworks disclosed it ceased operations and filed voluntary petitions for relief under the provisions of Chapter 7 of Title 11 of U.S Code.

    Shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) were down 53% to $1.5999. BioRestorative Therapies announced exercise of warrants and issuance of new warrants in a private placement for $8.1 million gross proceeds priced at-the-market.

    Peraso Inc. (NASDAQ:PRSO) was down, falling 48% to $1.60 after the company announced pricing of $4 million underwritten public offering.

    Also Check This Out: Top 5 Tech Stocks You May Want To Dump This Month

     

    Commodities

     

    In commodity news, oil traded up 0.2% to $72.90 while gold traded down 0.2% at $2,039.80.

    Silver traded down 0.3% to $22.36 on Tuesday while copper fell 0.1% to $3.77.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.1%, London’s FTSE 100 rose 0.5% while Spain’s IBEX 35 Index rose 0.2% The German DAX fell 0.1% French CAC 40 rose 0.2% while Italy’s FTSE MIB Index rose 0.3%.

    Retail sales in the Eurozone fell by 1.1% month-over-month in December versus a revised 0.3% increase in the prior month, while median consumer expectations for Eurozone inflation over the next 12 months declined for a third straight month to 3.2% in December. The HCOB Eurozone construction PMI fell to 41.3 in January from 43.6 a month ago.

    The S&P Global UK construction PMI climbed to 48.8 in January from 46.8 in the prior month. The S&P Global France construction PMI declined to 39.6 in January from 42.6 in December, while German construction PMI dipped to 36.3 from 37 in December.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Tuesday, with Japan’s Nikkei 225 falling 0.53%, Hong Kong’s Hang Seng Index jumping 4.04% and China’s Shanghai Composite Index gaining 3.23%. India’s S&P BSE Sensex, meanwhile, rose 0.63%.

    Household spending in Japan fell by 2.5% year-over-year in December compared to market expectations for a 2.1% decline. Average cash earnings in Japan rose by 1% year-over-year in December.

     

    Economics

     

    There are no major economic releases for Tuesday.

    Now Read This: Estée Lauder Analysts Increase Their Forecasts After Upbeat Earnings

    Get the next $AGFY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGFY
    $BRTX
    $LLY
    $NVIV

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    More analyst ratings

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

    Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br

    4/22/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

    Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels MELVILLE, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic partnership with David J. Goldberg, M.D., J.D., internationally recognized as one of the foremost innovators in laser dermatology, regenerative aesthetics, and clinical researc

    4/21/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    SEC Filings

    View All

    BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    4/23/26 5:12:57 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form DEFA14A filed by Tenax Therapeutics Inc.

    DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    4/22/26 8:19:57 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Tenax Therapeutics Inc.

    DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    4/22/26 8:17:37 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sulzberger Gabrielle

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:20:53 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Luciano Juan R

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:18:58 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fyrwald J Erik

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:16:39 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Leadership Updates

    Live Leadership Updates

    View All

    Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

    Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br

    4/22/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Financials

    Live finance-specific insights

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for first-quarter 2026 financial results announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heali

    4/16/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGFY
    $BRTX
    $LLY
    $NVIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care